FASgen, New Discovery in Obesity Research

Dec. 21, 2007 - FASgen is pleased to report the publication of important new research results in the obesity field using FAS89B, one of the Company's proprietary compounds. FASgen is a leader in the field of research into selective inhibition of fatty acid synthase (FASi), and has conducted extensive research in the area of metabolic disease disorders, specifically for the treatment of obesity and fatty liver disease... FASgen's Press Release -

Genaera, Positive Phase 1 Trodusquemine (MSI-1436)

October 25th, 2007 -- Genaera Corporation (NASDAQ: GENR) is providing the following summary of highlights related to the successful first Phase 1 study of trodusquemine and additional preclinical data expanding the support for selectivity and specificity of the drug in preclinical models from the North American Association for the Study of Obesity (NAASO) Annual Meeting in New Orleans... Genaera's Press Release -

Orexigen Therapeutics, Phase IIb Trial of Empatic to Treat Obesity

Oct 21, 2007 - Orexigen Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders including obesity, announced detailed results at the 24 week primary endpoint of its Phase IIb trial of Empatic, one of its two obesity drug candidates*... Orexigen's Press Release-

VIVUS, Qnexa Quality of Life Data

Oct. 22, 2007--VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, announced that Dr. Kishore Gadde presented the positive results of the Quality of Life data collected during the phase 2 clinical trial of Qnexa at the North America Association of the Study of Obesity (NAASO) 2007 Annual Scientific Meeting in New Orleans, LA... VIVUS' Press Release-

Orexigen Therapeutics, Third Phase III Trial for Contrave to Treat Obesity

Oct 17, 2007 - Orexigen™ Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders including obesity, announced the initiation of the third trial in its Phase III clinical trial program for its lead product candidate Contrave™ as a treatment for obesity. The program includes a set of four Phase III trials evaluating a variety of obesity-related outcome measures... Orexigen Therapeutics' Press Release-